Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.70 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL605221 | 1.00 | HRH4 (0.70) | HRH4ROCK1HTR3AHRH3 | |
| SCHEMBL18550569 | 1.00 | HRH4 (0.70) | HRH4ROCK1HTR3AHRH3 | |
| SCHEMBL605220 | 1.00 | HRH4 (0.70) | HRH4ROCK1HTR3AHRH3 | |
| SCHEMBL603940 | 0.84 | HRH4 (0.75) | HRH4ROCK1HTR3AHRH3 | |
| SCHEMBL603939 | 0.84 | HRH4 (0.75) | HRH4ROCK1HTR3AHRH3 | |
| SCHEMBL603941 | 0.84 | HRH4 (0.75) | HRH4ROCK1HTR3AHRH3 | |
| SCHEMBL1775551 | 0.83 | HRH4 (0.66) | HRH4ROCK1HTR3A | |
| SCHEMBL1775550 | 0.83 | HRH4 (0.66) | HRH4ROCK1HTR3A | |
| SCHEMBL602956 | 0.81 | HRH4 (0.70) | HRH4ROCK1HTR3AHRH3 | |
| SCHEMBL602957 | 0.81 | HRH4 (0.70) | HRH4ROCK1HTR3AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | disclosed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | disclosed |
| US-7923451-B2 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-12 | — | — | US | disclosed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | HRH4, HRH2, HRH3 | HRH4 1/4885ROCK1 4609/4885HTR3A 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.